Clinical and regulatory intelligence for Myelofibrosis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 2

Relevant assets

Geron →

INREBIC →

Relevant companies

Bristol Myers Squibb →

Eli Lilly →

Recent signals(3)

RegulatoryJuly 26, 2026

FDA Accepts Supplement for RYTELO (Imetelstat Sodium) by Geron

The FDA has accepted a supplemental application for RYTELO (Imetelstat Sodium) submitted by Geron.

RegulatoryJuly 24, 2026

FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

The FDA has approved a supplemental application for INREBIC, a treatment for myelofibrosis.

ClinicalJune 14, 2026

Lilly presents promising Phase 1 data for first-in-class type II JAK2 inhibitor in myelofibrosis

Lilly's AJ1-11095, a type II JAK2 inhibitor, shows an encouraging safety profile and promising clinical activity in myelofibrosis patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hematology →

Myelofibrosis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.